Transdermal Drug Delivery System Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3412
Transdermal Drug Delivery System Market size is expected to grow significantly from 2019 to 2025.
Transdermal drug delivery system market is estimated to witness lucrative growth over the coming years owing to rising prevalence of chronic diseases such as hypertension, diabetes, and angina across the world. As per world per organization, 60% of all deaths are due to chronic diseases. Aforementioned factors coupled with availability of third generation transdermal systems utilized in treatment of chronic diseases will stimulate the industry growth.
Advent in technology has led to development in drug delivery systems to support patient care. Recently developed transdermal drug delivery systems such as EMSAM and XULANE possess commendable efficiency and efficacy. Availability of such advanced systems will fuel business growth. However, complications associated with transdermal drug delivery systems, such as irritation at the site of application may impede its adoption affecting the business growth during forecast period.
Transdermal patches segment accounted for significant revenue share in 2018 and is estimated to follow similar trend during the forecast period. Rising adoption of transdermal patches due to reduced dosing frequency, improved bioavailability, reduced adverse events, and drug input termination at any point that will foster its demand. Moreover, transdermal patches are mostly preferred by elderly people as they have the tendency to forget intake of medications. Therefore, geriatric population relies on transdermal patches for managing medications that should spur the business growth.
Pain management segment will witness lucrative growth during the forecast period. Increasing burden of chronic pain worldwide and growing availability of superior quality transdermal products for pain management will positively influence segment growth during the forecast period. According to the National Center for Health Statistics, one in every four Americans have suffered from pain that lasts longer than 24 hours and millions more suffer from acute pain every year. Above mentioned factors surge demand for pain management transdermal products boosting segmental growth.
Homecare settings segment should witness robust growth during the forthcoming years owing to increasing patient preference towards transdermal drug delivery systems as they are convenient. Elderly population base susceptible to several diseases often prefer transdermal patches at homecare settings as they are cost effective and easy-to-use.
North America transdermal drug delivery system market held massive revenue share in 2018 and is estimated to witness similar trend throughout the analysis period. Rise in number of research activities related to transdermal drug delivery systems in North America will propel the regional market growth. Moreover, the rising prevalence of chronic diseases such as central nervous system disorders and cardiovascular diseases will further drive industry growth.
Some of the major players operating in transdermal drug delivery system industry include Hisamitsu Pharmaceutical, Mylan, UCB, Novartis and GlaxoSmithKline, Boehringer Ingelheim and Johnson & Johnson. Market players are adopting strategies such as novel product launch, partnerships and acquisitions to garner higher market share and sustain market competition. Moreover, receiving license for newly developed transdermal products will foster company’s growth. For instance, In July 2018, UCB has received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration. This will help the firm to enhance its sales.
Transdermal Drug Delivery System Market By Type, 2014-2025 (USD Million)
- Transdermal Patches
- Drug-In-Adhesive Patches
- Matrix Patches
- Reservoir Membrane Patches
- Microneedle Patches
- Transdermal Semisolids
Transdermal Drug Delivery System Market By Application, 2014-2025 (USD Million)
- Pain Management
- Hormonal Applications
- Testosterone Replacement Therapy
- Transdermal Estrogen Therapy
- Central Nervous System Disorders
- Cardiovascular Diseases
Transdermal Drug Delivery System Market By End-user, 2014-2025 (USD Million)
- Hospitals & clinics
- Homecare settings
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Boehringer Ingelheim
- Endo International
- Hisamitsu Pharmaceutical
- Johnson & Johnson
- Luye Pharma
- Purdue Pharma
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.